IL6 and COVID-19: In addition to tocilizumab, various additional monoclonal antibodies (mAbs) that have the potential to inhibit the physiological impacts of IL-6 are being evaluated in clinical studies for the treatment of COVID-19, including sarilumab, siltuximab, sirukumab (135, 136).